Betting on Vietnam’s future growth potential driven by landmark free trade agreements, investors from both the United States and the ASEAN are releasing new plans to venture further into the lucrative local market, with healthcare being a heavy focus.

Investing in research and development (R&D) and introducing innovative solutions that suit Vietnam’s disease patterns and ensuring that patients have better access to essential medicines and vaccines have been part of GSK’s tireless efforts in Vietnam. Dan Millard, Chief representative of GSK Pte. in Vietnam, talked to VIR’s Hoang Anh about GSK’s 25-year journey of accompanying Vietnamese healthcare professionals in the prevention and treatment of diseases in Vietnam, helping Vietnamese people to do more, feel better, and live longer.

Daniel Millard, chief representative of GSK Vietnam, discussed with VIR’s Bich Thuy about the company’s preparations for the EVFTA.